[Referral criteria for benign prostatic hyperplasia in primary care]

Area of Science:

• Urology
• Primary Care Medicine
• Health Management

Background:

• Benign prostatic hyperplasia (BPH) is highly prevalent in men over 50, necessitating coordinated care between primary care physicians and urologists.
• Lack of consensus on referral criteria complicates management, leading to potential delays or inappropriate interventions.
• Standardized diagnostic tools like the International Prostate Symptom Score (IPSS), digital rectal examination, and prostate-specific antigen (PSA) testing are crucial for accurate BPH diagnosis.

Framework:

• Develop clear referral guidelines to streamline patient management between primary care and specialist urology services.
• Integrate symptom assessment (IPSS), physical examination, and biomarker measurements (PSA) into a structured diagnostic and monitoring framework.
• Define specific thresholds for IPSS, PSA levels, and treatment response to guide urological referral decisions.

Implementation:

• Patients with IPSS < 8 require annual monitoring.
• For IPSS 8-20, treatment with alpha-blockers is recommended, with evaluations at 1 and 3 months. Larger prostates may warrant 5-alpha-reductase inhibitors, with 3 and 6-month evaluations.
• Combined treatment and 1 and 6-month evaluations are advised for large prostates with PSA > 1.5 ng/ml.

Implications:

• Establishes evidence-based criteria for referring BPH patients to urology, optimizing specialist resource utilization.
• Facilitates timely intervention for patients not responding to initial treatments or presenting with severe symptoms or complications.
• Aims to improve patient outcomes and healthcare efficiency in managing this common condition.